Objective To investigate the relationship between KRAS and BRAF gene mutations and prog⁃ nosis in colorectal cancer patients. Methods From January 2017 to January 2020，tissue samples from 60 patients with colorectal cancer submitted at the pathology department of our hospital were examined for KRAS and BRAF gene mutations using next⁃generation sequencing（NGS）technology. Analysis was done on the relationship between patient clinic pathological features and KRAS and BRAF gene mutations，as well as how these factors affected prog⁃ nosis. The COX regression model was employed to examine the variables affecting OS in CRC patients. Results The KRAS gene mutation rate of 60 colorectal cancer patients was 41.7%（25/60），t with the second exon mutation being the most common，and the BRAF gene mutation rate was 8.3%（5/60），all of which were exon 15 mutations with no co ⁃ mutation found. KRAS gene mutation is significantly related to pathological type and N stage，while BRAF gene mutation is mainly related to pathological type and distant metastasis. The disease control rate of KRAS mutation patients was significantly lower than that of wild ⁃type patients. Pathological type，T stage，N stage，and BRAF mutation are all independent factors that influence OS. BRAF mutation patients had significantly lower OS and PFS than wild⁃type patients，while KRAS mutation had no effect on OS and PFS. Conclusion KRAS mu⁃ tation rates were high in colorectal cancer，and they were closely related to patients′ degree of differentiation and lymph node metastasis. BARF mutation rates was low，which was related to the degree of differentiation，distant me⁃ tastasis，and poor prognosis.